Navigation Links
Echo Therapeutics Announces Second Quarter 2013 Financial Results
Date:8/8/2013

PHILADELPHIA, Aug. 8, 2013 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a medical device company developing its needle-free Symphony® CGM System as a non-invasive, wireless, continuous glucose monitoring system, today announced financial results for the quarter ended June 30, 2013.  Echo's Quarterly Report on Form 10-Q, as filed with the SEC, will be available by visiting the Investors section of Echo's website at www.echotx.com.

Recent Corporate Highlights

  • Echo initiated a multi-center clinical trial of its Symphony CGM System in critically ill patients.  The Company expects to complete the study in the third quarter, and will subsequently submit the CE Mark Technical File for marketing approval in Europe.
  • A pre-submission package was provided to the U.S. Food and Drug Administration (FDA) for its Symphony CGM System for use in the hospital critical care environment.  Echo has scheduled a meeting with the FDA in the third quarter to obtain the FDA's guidance regarding the U.S. regulatory pathway for Symphony, the proper approach to refining the pivotal trial protocol and endpoints, and preparing the pre-marketing application.
  • Echo completed a public offering of approximately $11.3 million, after expenses, in June.
  • Echo received agreement on its clinical trial plan from its Notified Body in Europe and Institutional Review Board (IRB) approval from each of its four US clinical study sites for the clinical study supporting CE Marking for its Symphony CGM System.
  • Echo demonstrated the features and functionality of the Symphony CGM System in the critical care setting during a live webcast following the annual stockholders meeting in May.  Management plans additional
    '/>"/>

  • SOURCE Echo Therapeutics, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5

    Related medicine technology :

    1. Pain Therapeutics - Drugs, Markets and Companies - 2013 Report
    2. Orexigen Therapeutics Announces European Filing Strategy and Reports Business and Financial Results for the Second Quarter Ended June 30, 2013
    3. Echo Therapeutics Schedules Second Quarter 2013 Financial Results for Thursday, August 8, 2013
    4. Prime Therapeutics adds 80 new jobs in Albuquerque
    5. Lightlake Therapeutics Retains KCSA Strategic Communications as Corporate Communications Advisors
    6. PTC Therapeutics To Host Second Quarter 2013 Financial Results Conference Call And Webcast
    7. Cell Therapeutics Reports Second Quarter 2013 Financial Results
    8. AuraSense Therapeutics Closes Tranche II of Series B Equity Investment
    9. Covington Advises Actelion in Acquisition of Ceptaris Therapeutics
    10. Oncos Therapeutics Granted Orphan Drug Designation for CGTG-102 in Soft Tissue Sarcoma (STS) by FDA and EMA
    11. Diabetes Therapeutics Market in India to 2018 - Rapid Uptake of DPP-IV Inhibitors, GLP-1 Agonists and Expanding Insulin Segment to Drive Growth
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/23/2015)... , Jan. 23, 2015  Lixte Biotechnology Holdings, Inc. (OTCQB: ... Phase I trial of Lixte,s lead compound, LB‑100, is being ... John S. Kovach , M.D., the founder and ... to be completed at a single site. Accrual of patients, ...
    (Date:1/23/2015)... Ala. , Jan. 23, 2015 Gem Pharmaceuticals ... patients have been enrolled into the Company,s Phase 2 ... and safety of Gem,s lead compound, GPX-150 (an investigational ... advanced or metastatic disease. Logo - ...
    (Date:1/22/2015)...  Uroplasty, Inc. (NASDAQ: UPI ), a medical device ... to treat voiding dysfunctions, today reported financial results for ... Global revenue for the Company,s Urgent ®  PC ... quarterly revenue record, as compared to $3.9 million in ...
    Breaking Medicine Technology:Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3Gem Pharmaceuticals Announces Enrollment of Initial Patients in its Phase 2 Clinical Trial to Assess the Efficacy and Safety of GPX-150 in Sarcoma Patients 2Uroplasty Reports Record Revenue in Fiscal Third Quarter 2Uroplasty Reports Record Revenue in Fiscal Third Quarter 3Uroplasty Reports Record Revenue in Fiscal Third Quarter 4Uroplasty Reports Record Revenue in Fiscal Third Quarter 5Uroplasty Reports Record Revenue in Fiscal Third Quarter 6Uroplasty Reports Record Revenue in Fiscal Third Quarter 7Uroplasty Reports Record Revenue in Fiscal Third Quarter 8Uroplasty Reports Record Revenue in Fiscal Third Quarter 9Uroplasty Reports Record Revenue in Fiscal Third Quarter 10Uroplasty Reports Record Revenue in Fiscal Third Quarter 11Uroplasty Reports Record Revenue in Fiscal Third Quarter 12Uroplasty Reports Record Revenue in Fiscal Third Quarter 13Uroplasty Reports Record Revenue in Fiscal Third Quarter 14Uroplasty Reports Record Revenue in Fiscal Third Quarter 15Uroplasty Reports Record Revenue in Fiscal Third Quarter 16Uroplasty Reports Record Revenue in Fiscal Third Quarter 17Uroplasty Reports Record Revenue in Fiscal Third Quarter 18
    ... 2, 2011 Lixte Biotechnology Holdings ... company has received a $244,479.25 grant under the ... further development and commercialization of Lixte,s novel anti-cancer compound LB-100. ... Protection and Affordable Care Act of 2010 to encourage development ...
    ... 2011 Joslin Diabetes Center has launched a groundbreaking ... Joslin, with technology from Forward Health Group, Inc., is ... with the critical capability to extract usefulness out of ... to combine this information with practice improvement support and ...
    Cached Medicine Technology:Lixte Biotechnology Holdings, Inc. Awarded Grant Under Qualifying Therapeutic Discovery Project from the U. S. Government 2Joslin Diabetes Center Launches Initiative to Resolve the Critical Link Connecting Continuing Medical Education (CME) to Sustained Quality Improvement 2Joslin Diabetes Center Launches Initiative to Resolve the Critical Link Connecting Continuing Medical Education (CME) to Sustained Quality Improvement 3
    (Date:1/22/2015)... January 23, 2015 VogueQueen is a seasoned ... prices and many designers are thrilled to have it lead ... announces its new collection of prom dresses for the global ... drive the strategic vision and he focuses on continuing the ...
    (Date:1/22/2015)... (PRWEB) January 22, 2015 The federal court ... the U.S. District Court, Southern District of West Virginia has ... in that proceeding’s first bellwether trial. In an Order dated ... new trial after finding that C.R. Bard had not proven ...
    (Date:1/22/2015)... Oceanside,CA (PRWEB) January 22, 2015 For over 20 ... the Oceanside and Vista area has treated just about ... other personal injury circumstances. And for those same twenty-plus years, ... victims of all those injuries with the best possible doctor. ...
    (Date:1/22/2015)... Recently, Weddingshe.com has added many trendy Champagne wedding ... revenues in the past three years. Today, the business announces ... According to the sales manager of the company, this is ... 2015. This point can be reflected on the discounted wedding ...
    (Date:1/22/2015)... As interest in the value of spiritual support as ... Rev. Eric J. Hall , president and CEO of the ... the keynote speaker on January 27 at an international summit ... The conference, “Hope and Resilience: Innovative and Interdisciplinary Spiritual Care,” ...
    Breaking Medicine News(10 mins):Health News:VogueQueen Unveils New Designs of Prom Dresses for 2015 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:Weddingshe Announces A Special Offer On Its Popular Glamorous Wedding Dresses 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 3
    ... patch for current drug both control symptoms better, studies ... new medication and an improved delivery system for an ... symptoms of Parkinson,s disease. , In the first study, ... typical Parkinson,s symptoms, such as tremors and slowness of ...
    ... June 2008 - Elsevier announced today Reproductive Health ... "Conflict and Crisis Settings: Promoting Sexual and Reproductive rights". ... well as rampant militarism, growing numbers of refugees and ... rights or even ,the right to have rights,. ...
    ... could someday be used routinely to help paralyzed patients ... Now, University of Florida researchers have taken the concept ... not only to translate brain signals into movement but ... , Instead of simply interpreting brain signals and routing ...
    ... the medical spa trend but doing little to ... advocate their own safety within the facility, CHICAGO, June ... results from a consumer survey asking 1,000 women,their opinions on ... 2001, are the primary customers of these facilities.,Yet half of ...
    ... The Rehabilitation Institute,of Chicago and MediCom Worldwide, ... Pain July 18th and 19th. The meeting will ... Northwestern University in Chicago., This year, the ... The scientific agenda will focus on the latest ...
    ... With a latency period of 10-50,years, and with ... the ravages of this life ending disease continue,to disrupt ... press,conference with leadership, members of Congress and three guest ... to mesothelioma., The press conference will be held ...
    Cached Medicine News:Health News:New Hope for Parkinson's Patients 2Health News:May 2008 issue on conflict and crisis settings: Promoting sexual and reproductive rights 2Health News:Researchers develop neural implant that learns with the brain 2Health News:Researchers develop neural implant that learns with the brain 3Health News:Millennials' Medspa Influence 2Health News:3rd Annual Conference on Pain Jointly Sponsored By Rehabilitation Institute of Chicago and MediCom Worldwide, Inc. 2Health News:Faces of Mesothelioma; Meso Foundation Press Conference with Families and Patients 2
    ... AQuify provides a completely new level ... and lubrication of both the lens ... This blink-activated product contains sodium hyalunorate, ... tear behavior on the eye. With ...
    Lens Plus rewetting drops for soft contact lenses....
    Renu rewetting drops soothe your eyes and moisturize soft contact lenses to minimize dryness....
    For use to rewet and lubricate lenses during wear. Soothes and moisturizes eyes while wearing soft contact lenses....
    Medicine Products: